Market Research Logo

Sickle Cell Disease - Pipeline Review, H1 2015

Sickle Cell Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Sickle Cell Disease - Pipeline Review, H1 2015’, provides an overview of the Sickle Cell Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sickle Cell Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sickle Cell Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sickle Cell Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sickle Cell Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sickle Cell Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Sickle Cell Disease Overview
Therapeutics Development
Pipeline Products for Sickle Cell Disease - Overview
Pipeline Products for Sickle Cell Disease - Comparative Analysis
Sickle Cell Disease - Therapeutics under Development by Companies
Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes
Sickle Cell Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Sickle Cell Disease - Products under Development by Companies
Sickle Cell Disease - Products under Investigation by Universities/Institutes
Sickle Cell Disease - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Alnylam Pharmaceuticals, Inc.
Bluebird bio, Inc.
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Dilaforette AB
Emmaus Medical, Inc.
Errant Gene Therapeutics, LLC
Erytech Pharma SA
Gamida Cell Ltd.
Gilead Sciences, Inc.
Global Blood Therapeutics, Inc.
Isis Pharmaceuticals, Inc.
Johnson & Johnson
Morphogenesis, Inc.
NKT Therapeutics, Inc.
Novartis AG
Pfizer Inc.
PharmaEssentia Corporation
Prolong Pharmaceuticals
ReveraGen BioPharma, Inc.
Sangamo BioSciences, Inc.
Sanofi
SynZyme Technologies, LLC
Sickle Cell Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACY-957 - Drug Profile
ADX-85142 - Drug Profile
ADX-94819 - Drug Profile
AIC-2011 - Drug Profile
AIC-6020 - Drug Profile
ALN-TMP - Drug Profile
Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders - Drug Profile
apixaban - Drug Profile
BAX-555 - Drug Profile
BB-305 - Drug Profile
CNTO-530 - Drug Profile
Didox - Drug Profile
Drugs to Inhibit PRMT5 for Sickle Cell Anemia - Drug Profile
EdX-17 - Drug Profile
Enhoxy - Drug Profile
GBT-440 - Drug Profile
Gene Therapy for Sickle Cell Anemia - Drug Profile
Gene Therapy for Sickle Cell Disease - Drug Profile
Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile
Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile
Gene Therapy to Activate Gamma Globin for Sickle Cell Disease - Drug Profile
glutamine - Drug Profile
luspatercept - Drug Profile
NiCord - Drug Profile
NKTT-120 - Drug Profile
panobinostat - Drug Profile
PB-04 - Drug Profile
PF-4447943 - Drug Profile
plerixafor - Drug Profile
PNQ-103 - Drug Profile
prasugrel hydrochloride - Drug Profile
Protein for Sickle Cell Disease - Drug Profile
regadenoson - Drug Profile
RN-1 - Drug Profile
Sanguinate - Drug Profile
SCD-101 - Drug Profile
SCPF - Drug Profile
sevuparin sodium - Drug Profile
Small Molecule for Beta Thalassemia and Sickle Cell Anemia - Drug Profile
Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile
Small Molecule to Inhibit KDM1A for AML, MDS and Sickle Cell Disease - Drug Profile
Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile
Small Molecules to Inhibit HDAC for Oncology and Sickle Cell Disease - Drug Profile
Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile
Stem Cell Therapy to Activate Beta Globin for Sickle Cell Disease - Drug Profile
Trichosic - Drug Profile
VBP-15 - Drug Profile
VitalHeme - Drug Profile
Sickle Cell Disease - Recent Pipeline Updates
Sickle Cell Disease - Dormant Projects
Sickle Cell Disease - Discontinued Products
Sickle Cell Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sickle Cell Disease, H1 2015
Number of Products under Development for Sickle Cell Disease - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Sickle Cell Disease - Pipeline by Acceleron Pharma, Inc., H1 2015
Sickle Cell Disease - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015
Sickle Cell Disease - Pipeline by Addex Therapeutics Ltd, H1 2015
Sickle Cell Disease - Pipeline by Advinus Therapeutics Ltd., H1 2015
Sickle Cell Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015
Sickle Cell Disease - Pipeline by Bluebird bio, Inc., H1 2015
Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Company, H1 2015
Sickle Cell Disease - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Sickle Cell Disease - Pipeline by Dilaforette AB, H1 2015
Sickle Cell Disease - Pipeline by Emmaus Medical, Inc., H1 2015
Sickle Cell Disease - Pipeline by Errant Gene Therapeutics, LLC, H1 2015
Sickle Cell Disease - Pipeline by Erytech Pharma SA, H1 2015
Sickle Cell Disease - Pipeline by Gamida Cell Ltd., H1 2015
Sickle Cell Disease - Pipeline by Gilead Sciences, Inc., H1 2015
Sickle Cell Disease - Pipeline by Global Blood Therapeutics, Inc., H1 2015
Sickle Cell Disease - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Sickle Cell Disease - Pipeline by Johnson & Johnson, H1 2015
Sickle Cell Disease - Pipeline by Morphogenesis, Inc., H1 2015
Sickle Cell Disease - Pipeline by NKT Therapeutics, Inc., H1 2015
Sickle Cell Disease - Pipeline by Novartis AG, H1 2015
Sickle Cell Disease - Pipeline by Pfizer Inc., H1 2015
Sickle Cell Disease - Pipeline by PharmaEssentia Corporation, H1 2015
Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals, H1 2015
Sickle Cell Disease - Pipeline by ReveraGen BioPharma, Inc., H1 2015
Sickle Cell Disease - Pipeline by Sangamo BioSciences, Inc., H1 2015
Sickle Cell Disease - Pipeline by Sanofi, H1 2015
Sickle Cell Disease - Pipeline by SynZyme Technologies, LLC, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Sickle Cell Disease Therapeutics - Recent Pipeline Updates, H1 2015
Sickle Cell Disease - Dormant Projects, H1 2015
Sickle Cell Disease - Dormant Projects (Contd..1), H1 2015
Sickle Cell Disease - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Sickle Cell Disease, H1 2015
Number of Products under Development for Sickle Cell Disease - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report